Matt Kapusta, uniQure
June 22, 2021 02:51 PM EDTUpdated 04:27 PM
Deals
FDA+

With FDA fil­ing for key gene ther­a­py pushed back 6 months, uniQure opens the pock­et­book to re­fresh the pipeline

Kyle Blankenship

Once fac­ing a ma­jor set­back for its lead gene ther­a­py pro­gram for he­mo­phil­ia B, uniQure saw a sliv­er of light when the FDA lift­ed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times